Increasing Azithromycin Resistance in Neisseria gonorrhoeae Due to NG-MAST 12302 Clonal Spread in Canada, 2015 to 2018.
NG-MAST
azithromycin-resistant gonorrhea
whole-genome sequencing
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
15 03 2022
15 03 2022
Historique:
pubmed:
4
1
2022
medline:
24
3
2022
entrez:
3
1
2022
Statut:
ppublish
Résumé
Azithromycin-resistant (AZIR) gonorrhea has been steadily increasing in Canada over the past decade, which is cause for alarm, as azithromycin (AZI) has been part of the combination therapy recommended by the Canadian Guidelines on Sexually Transmitted Infections (CGSTI) since 2012. Neisseria gonorrhoeae with AZI MICs ≥1 mg/L collected between 2015 and 2018 as part of the Gonococcal Antimicrobial Surveillance Program-Canada underwent antimicrobial susceptibility testing, molecular typing, and whole-genome sequencing. Regional, demographic, and clinical isolation site comparisons were made to aid in our understanding of AZI susceptibility trending. We identified 3,447 N. gonorrhoeae with AZI MICs of ≥1 mg/L in Canada, which increased from 6.3% in 2015 to 26.5% of isolates in 2018. Central Canada had the highest proportion, rising from 9.2% in 2015 to 31.2% in 2018. We identified 273 different N. gonorrhoeae multiantigen sequence types (NG-MAST) among these isolates, with ST-12302 the most prevalent (50.9%). Whole-genome sequencing identified the Neisseria lactamica-like mosaic
Identifiants
pubmed: 34978884
doi: 10.1128/AAC.01688-21
pmc: PMC8923198
doi:
Substances chimiques
Anti-Bacterial Agents
0
Azithromycin
83905-01-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0168821Références
Euro Surveill. 2018 Jul;23(27):
pubmed: 29991383
Lancet Infect Dis. 2018 Jul;18(7):717-718
pubmed: 29976521
PLoS One. 2017 Mar 28;12(3):e0174372
pubmed: 28350806
Emerg Infect Dis. 2019 Sep;25(9):1660-1667
pubmed: 31407661
Antimicrob Agents Chemother. 2021 Jan 20;65(2):
pubmed: 33139288
Clin Microbiol Rev. 2014 Jul;27(3):587-613
pubmed: 24982323
mBio. 2018 Aug 7;9(4):
pubmed: 30087172
J Infect Dis. 2004 Apr 15;189(8):1497-505
pubmed: 15073688
J Antimicrob Chemother. 2020 Feb 1;75(2):449-457
pubmed: 31670808
Lancet Microbe. 2020 Aug;1(4):e154-e164
pubmed: 33005903
JAMA. 2013 Jan 9;309(2):163-70
pubmed: 23299608
Lancet Infect Dis. 2020 Mar;20(3):276-278
pubmed: 32112753
J Infect Chemother. 2016 Dec;22(12):841-843
pubmed: 27578029
Euro Surveill. 2019 Mar;24(10):
pubmed: 30862336
Antimicrob Agents Chemother. 2019 Aug 23;63(9):
pubmed: 31235631
Antimicrob Agents Chemother. 2020 Apr 21;64(5):
pubmed: 32071056
Bull World Health Organ. 2019 Aug 1;97(8):548-562P
pubmed: 31384073
J Antimicrob Chemother. 2015 Dec;70(12):3404-5
pubmed: 26316384
Antibiotics (Basel). 2018 Jul 13;7(3):
pubmed: 30011825
PLoS Med. 2017 Jul 7;14(7):e1002344
pubmed: 28686231
Clin Infect Dis. 2017 Sep 15;65(6):918-923
pubmed: 28549097
FEBS Lett. 2020 Aug;594(16):2670-2694
pubmed: 32058583
BMC Bioinformatics. 2013 Nov 06;14:317
pubmed: 24191891
Microb Genom. 2017 Jun 8;3(6):e000116
pubmed: 29026651
BMC Microbiol. 2020 Aug 11;20(1):247
pubmed: 32782021
Lancet Infect Dis. 2018 May;18(5):573-581
pubmed: 29523496
mBio. 2018 Nov 27;9(6):
pubmed: 30482834
Genome Med. 2021 Apr 19;13(1):61
pubmed: 33875000
J Clin Microbiol. 2016 May;54(5):1304-13
pubmed: 26935729
Sex Transm Infect. 2016 Aug;92(5):365-7
pubmed: 26601852
Front Microbiol. 2018 Nov 20;9:2688
pubmed: 30515136
PLoS One. 2019 Apr 3;14(4):e0213312
pubmed: 30943199
J Infect Dis. 2021 Oct 28;224(8):1398-1404
pubmed: 33592101
Antimicrob Agents Chemother. 2020 Feb 21;64(3):
pubmed: 31871081
J Antimicrob Chemother. 2016 Sep;71(9):2471-8
pubmed: 27301565
Antimicrob Agents Chemother. 2012 Mar;56(3):1273-80
pubmed: 22155830
Euro Surveill. 2019 Feb;24(8):
pubmed: 30808445
Antimicrob Agents Chemother. 2010 Apr;54(4):1652-3
pubmed: 20123998
J Mol Diagn. 2013 Jan;15(1):116-29
pubmed: 23159594